Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib in Advanced Malignancies and Hepatic Impairment
NCT07422610Phase 1Recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Primary completion
- Jun 2028
- Countries
- 4
01
Overview
Phase 1, open-label trial of pelabresib in advanced cancer (2 arms), sponsored by Novartis. Primary endpoints: Area Under the Curve from 0 to 24 hours, Maximum Plasma Concentration at Day 14 and 3 more. Started May 2026; status: recruiting.
02
Drugs
pelabresib
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT07422610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422610.